Alogliptin: a review of its use in patients with type 2 diabetes mellitus (Q38412153)

2 September 2017

1 reference

title

Alogliptin: a review of its use in patients with type 2 diabetes mellitus (English)

1 reference

2 September 2017

1 reference

1

Gillian M Keating

1 reference

2 September 2017

1 May 2015

1 reference

2 September 2017

1 reference

2 September 2017

75

1 reference

2 September 2017

7

1 reference

2 September 2017

777-796

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-015-0385-y

2 September 2017

0 references

cites work

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Alogliptin: safety, efficacy, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0385-Y

Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin

21 January 2018

1 reference

12 December 2020

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study

1 reference

12 December 2020

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.

1 reference

12 December 2020

Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase

1 reference

12 December 2020

Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk

1 reference

12 December 2020

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.

1 reference

12 December 2020

Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study

1 reference

12 December 2020

10.1007/S40265-015-0385-Y

Identifiers

DOI

1 reference

PubMed ID

25855222

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25855222